How Long Does Tirzepatide Stay in Your System? (Mounjaro, Zepbound)
Tirzepatide has a half-life of about 5 days, so after your last weekly shot the drug keeps working its way out of your blood for roughly 25 days — about five half-lives. Here's what the labels and FDA review actually say.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Tirzepatide (the active drug in Mounjaro and Zepbound) has a terminal half-life of about 5 days, with a plasma clearance of 0.061 L/h [6]. A population pharmacokinetic model built from 19 pooled studies reached the same conclusion: a half-life of roughly 5 days, which is what makes sustained once-weekly dosing possible [3]. That means after a single injection, about half the drug in your bloodstream is gone after 5 days, half of what’s left is gone after another 5 days, and so on.
Working from that 5-day half-life, the arithmetic works out to about 25 days — five half-lives — for the drug to be effectively cleared from plasma after the last shot. That 25-day figure is a calculation, not a number stated in the FDA label or the clinical pharmacology review; those documents state only the ~5-day half-life [6]. Both Mounjaro and Zepbound contain tirzepatide [1][2], and the half-life figures above come from studies of tirzepatide itself.
What does half-life mean, and where does the 5-day number come from?
A half-life is the time it takes for the concentration of a drug in the blood to fall by half. It does not mean the drug is gone in 5 days — it means half of it is gone, then half of the remainder over the next 5 days, and so on. This is why the standard rule of thumb is about five half-lives for near-complete clearance, which for tirzepatide works out to roughly 25 days.
The 5-day figure comes from more than one analysis. The FDA clinical pharmacology review lists a terminal half-life of approximately 5 days [6]. A population pharmacokinetic (popPK) model, built from 19 pooled studies — including healthy volunteers, people with renal impairment, people with hepatic impairment, and people with type 2 diabetes in phase 1, 2, and 3 trials — also found a half-life of about 5 days and concluded it supports sustained exposure with once-weekly subcutaneous dosing [3]. That model described tirzepatide’s behavior with a two-compartment model using first-order absorption and elimination [3].
A separate phase 1 multiple-ascending-dose study in Japanese adults with type 2 diabetes, run over 8 weeks with 48 randomized participants, likewise reported a plasma half-life of approximately 5 days [4]. In that study the 5 mg group received 5 mg weekly for the full 8 weeks, while the 10 mg and 15 mg groups reached their target doses by stepwise escalation — the 10 mg group through 2.5 mg and 5 mg steps, the 15 mg group through 5 mg and 10 mg steps [4].
Why does tirzepatide last days instead of minutes?
Tirzepatide is a 39-amino-acid synthetic peptide engineered from the GIP amino acid sequence [4][6]. The molecule includes a C20 fatty diacid moiety that enables binding to albumin, and that albumin binding is what allows once-weekly dosing [4]. Consistent with that design, plasma protein binding is 99% [6].
The molecule is a dual agonist at the GIP and GLP-1 receptors, and at the GLP-1 receptor it acts as a biased agonist, preferentially signaling through activation of adenylyl cyclase rather than recruitment of β-arrestin [6].
How fast does a single shot peak, and how much gets in?
After a subcutaneous injection, the time to reach maximum plasma concentration (Tmax) ranges from 8 to 72 hours [6]. Absolute bioavailability is approximately 80%, and the apparent volume of distribution at steady state is 10.3 L [6]. Pharmacokinetics are dose-proportional across the range of 0.25 to 15 mg based on the population PK analysis [6].
The label directs injection into the abdomen, thigh, or upper arm — with the back of the upper arm injected by another person — and rotation of injection sites with each dose [1][6].
Does the drug build up when you start or increase a dose?
Yes. Steady state — the point where weekly doses no longer push blood levels higher — is reached at 4 weeks of once-weekly dosing [6].
The escalation schedules in the labels reflect this. Mounjaro starts at 2.5 mg subcutaneously once weekly, with increases in 2.5 mg increments after at least 4 weeks on the current dose; the adult maximum is 15 mg weekly, and the maximum for pediatric patients 10 and older is 10 mg weekly [1]. Zepbound starts at 2.5 mg weekly for 4 weeks — a dose the label describes as for initiation only, not a maintenance dose — then moves to 5 mg, with further 2.5 mg increases after at least 4 weeks on the current dose [2]. Zepbound maintenance dosages are 5, 10, or 15 mg weekly for weight, and 10 or 15 mg weekly for obstructive sleep apnea, with a maximum of 15 mg [2]. Both labels state the purpose of the escalation schedule: to reduce the risk of gastrointestinal adverse reactions [1][2].
What happens if you miss a dose?
The Mounjaro label says that if a dose is missed, it should be administered as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, the missed dose should be skipped and the next dose taken on the regularly scheduled day, after which the regular weekly schedule resumes [1]. The FDA clinical pharmacology review restates the same 4-day window [6].
The weekly injection day can be changed if needed, as long as at least 3 days (72 hours) separate the two doses [1]. For comparison, the Ozempic (semaglutide) label — a different molecule — allows a missed dose to be administered within 5 days [5].
What if you’ve missed several weeks of doses?
The Mounjaro and Zepbound label excerpts do not include a restart schedule for prolonged lapses; the missed-dose instructions cover only the 4-day window [1]. One clinical conversion guide, from Beth Israel Lahey Health and covering brands indicated for type 2 diabetes, offers suggestions for resuming tirzepatide after a lapse. For people whose last dose was 5 mg or higher once weekly: if fewer than 2 doses were missed, the guide suggests resuming the same dose, provided it was previously tolerated. If 3 or more doses were missed, the guide suggests reinitiating at 5 mg once weekly, and considering 2.5 mg instead if there were gastrointestinal side effects in the past [7].
That guide states it does not replace clinical judgment, so any restart decision rests with the prescriber [7].
How does the body get rid of tirzepatide?
Tirzepatide is broken down by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis [6]. Renal excretion is the primary route of elimination, but the intact parent drug is not detected in urine or feces — what leaves the body are metabolites [6]. Approximately 70% of a radiolabeled dose is recovered as metabolites, about 50% in urine and 20% in feces [6].
Do kidney or liver problems, age, or body weight change how long tirzepatide stays in your body?
No dose adjustment is considered necessary for age, gender, body weight, race, renal impairment, hepatic impairment, or drug interactions, according to the FDA clinical pharmacology review [6]. The popPK covariate analysis reached the same conclusion for renal impairment, hepatic impairment, body weight, sex, age, race, and ethnicity [3]. That analysis drew on dedicated single-dose 5 mg phase 1 studies in people with renal impairment and in people with hepatic impairment [3].
One label precaution is worth noting: the labels advise monitoring renal function in patients reporting adverse reactions that could lead to volume depletion, because of the risk of acute kidney injury [1][2].
Is the drug leaving your blood the same as the effects wearing off?
Not exactly. Tirzepatide slows gastric emptying, and the FDA review notes this effect diminishes over time [6]. A pharmacodynamic study found the delay in gastric emptying is transient, similar to what is seen with selective long-acting GLP-1 receptor agonists [9].
The delayed gastric emptying can affect the absorption of other oral medications taken at the same time [1][2]. The labels give one specific instruction on this point: females using oral contraceptives are advised to switch to a non-oral method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation [1][2].
The supplied label and review texts describe the drug’s presence in plasma, not the time course of effects after stopping.
How long before surgery or anesthesia should you stop the shot?
The labels do not give a number of days to stop before surgery. What they do say is that pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures, and that patients should inform their healthcare providers of any planned surgeries or procedures [1][2]. The decision about whether and when to hold the injection before a procedure belongs to the surgical and prescribing team, not to a label-stated interval.
How long before trying to conceive should you stop?
The Mounjaro label says that based on animal studies, the drug may cause fetal harm [1], and the Zepbound label says it may cause fetal harm and should be discontinued when pregnancy is recognized [2]. Neither label excerpt specifies how many weeks or months to stop beforehand.
For comparison, the Ozempic (semaglutide) label — a different molecule with its own clearance — instructs discontinuing at least 2 months before a planned pregnancy, citing the long washout period for semaglutide [5]. That 2-month figure applies to semaglutide and is not stated for tirzepatide.
Key numbers at a glance
| Measurement | Value |
|---|---|
| Terminal half-life | ~5 days [6] |
| Plasma clearance | 0.061 L/h [6] |
| Time to peak concentration (Tmax) | 8 to 72 hours [6] |
| Absolute bioavailability | ~80% [6] |
| Plasma protein binding | 99% [6] |
| Volume of distribution at steady state | 10.3 L [6] |
| Steady state reached | 4 weeks of once-weekly dosing [6] |
| Missed-dose window | 4 days (96 hours) [1] |
| Minimum spacing when changing injection day | 3 days (72 hours) [1] |
| Excretion of metabolites | ~50% urine, ~20% feces; no intact drug detected [6] |
| Approximate time to near-complete clearance after last shot | ~25 days (arithmetic: 5 half-lives × ~5 days) [6] |
One more note on scope: these figures come from the approved products and their FDA review. Compounded or otherwise non-FDA-approved tirzepatide is not covered by these sources, and its behavior cannot be assumed to match.
Sources
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information.
- CPT: Pharmacometrics & Systems Pharmacology. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. 2024.
- A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
- DailyMed. OZEMPIC- semaglutide injection, solution.
- US Food and Drug Administration. Clinical pharmacology review, NDA 215866 (Mounjaro/tirzepatide).
- Beth Israel Lahey Health. GLP-1RA and dual GLP-1RA/GIP: conversions and therapy gap management guide. Updated August 2024.
- US Food and Drug Administration. Clinical pharmacology review for NDA 215866 (tirzepatide, Mounjaro).
- Diabetes, Obesity and Metabolism. Tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. 2020.
- PubMed. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN).
- The Journal of Clinical Endocrinology & Metabolism. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide.
- Cureus. Glucagon-like peptide-1 receptor agonists and reproductive health: a narrative review for obstetrician-gynecologists.
Frequently asked questions
How many days until tirzepatide is fully cleared after my last shot?
Tirzepatide's half-life is about 5 days. Five half-lives — roughly 25 days — is the standard arithmetic for near-complete clearance, but that 25-day figure is a calculation, not a number stated in the FDA label or clinical pharmacology review.
Does tirzepatide clear faster or slower than semaglutide (Ozempic, Wegovy)?
The supplied tirzepatide documents state only tirzepatide's ~5-day half-life. The Ozempic label does cite a long washout period for semaglutide in advising discontinuation at least 2 months before a planned pregnancy.
How long until appetite and side effects come back after stopping?
What is documented is that tirzepatide's slowing of gastric emptying diminishes over time during treatment and is transient, similar to selective long-acting GLP-1 receptor agonists.
Does tirzepatide show up on a standard drug test or blood test?
No supplied source addresses drug screening or routine blood testing for tirzepatide, so nothing can be stated about detection windows. The pharmacology data describe plasma concentrations in study settings, not screening tests.
What should I do after missing one week, two weeks, or a month of doses?
The label covers only a 4-day (96-hour) window: take the missed dose as soon as possible within 4 days, otherwise skip it and resume the regular schedule. For longer lapses, a BILH conversion guide suggests resuming the same dose if fewer than 2 doses were missed, and reinitiating at 5 mg weekly (or considering 2.5 mg after prior GI side effects) if 3 or more were missed — while stating it does not replace clinical judgment.
Does kidney or liver disease make tirzepatide linger longer?
No dose adjustment is considered necessary for renal or hepatic impairment, or for age, sex, body weight, or race, per the FDA review and the popPK covariate analysis, which included dedicated renal- and hepatic-impairment studies. The labels still advise monitoring renal function if adverse reactions cause volume depletion.
How long before surgery or anesthesia should I stop tirzepatide?
The labels give no stop-days number. They report pulmonary aspiration during general anesthesia or deep sedation with GLP-1 receptor agonists and instruct patients to inform healthcare providers of planned surgeries or procedures. Timing of any hold is a decision for the care team.
How long before trying to conceive should I stop tirzepatide?
The tirzepatide labels state the drug may cause fetal harm and that Zepbound should be discontinued when pregnancy is recognized. The 2-month preconception stop in the Ozempic label applies to semaglutide, a different molecule.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.